Searchable abstracts of presentations at key conferences in endocrinology

ea0038n1.1 | Nurse Session 1: Multiple Endocrine Neoplasia | SFEBES2015

Overview of multiple endocrine neoplasia

Ayuk John

Multiple endocrine neoplasia (MEN) syndromes are rare autosomal-dominant disorders that predispose affected individuals to benign and malignant tumours involving two or more endocrine glands. Four major forms of MEN are recognised, each associated with the occurrence of specific tumours. MEN1 is due to germline-inactivating mutations of the MEN1 tumour-suppressor gene, and is associated with the occurrence of parathyroid, pancreatic islet and anterior pituitary tumours. MEN2 (...

ea0038p308 | Pituitary | SFEBES2015

Antisense oligomer therapy directed at the GH receptor is associated with reduction in circulating GHBP levels

Trainer Peter , Newell-Price John , Ayuk John , Aylwin Simon , Rees Aled , Drake Will , Chanson Philippe , Brue Thierry , Webb Susan , Fajardo Carmen , Aller Javier , McCormack Ann , Torpy David , Atley Lynne , Tachas George

ATL1103 is a second generation antisense 20mer intended to inhibit expression of the GH receptor (GHR) gene. Phosphorothioate and 2′-O-methoxyethyl modifications to nucleotides increase its plasma half-life and affinity for the target RNA to allow post-hybridization RNaseH degradation. We previously reported a phase 2, randomised, open-label, parallel group study of ATL1103 in 26 patients with acromegaly which demonstrated a fall in serum IGF-I of 26% with 200 mg twice w...

ea0037gp.19.10 | Pituitary–Acromegaly | ECE2015

A phase 2 study of antisense oligonucleotide therapy directed at the GH receptor demonstrates lowering of serum IGF1 in patients with acromegaly.

Trainer Peter , Newell-Price John , Ayuk John , Aylwin Simon , Rees Aled , Drake Will , Chanson Philippe , Brue Thierry , Webb Susan , Fajardo Carmen , Aller Javier , McCormack Ann , Torpy David , Tachas George , Atley Lynne , Bidlingmaier Martin

ATL1103 is a second generation antisense oligomer directed at the GH receptor. It is a 20mer with a phosphorothioate backbone and 2′-O-methoxyethyl modifications of the five nucleotides at either end intended to increase its plasma half-life and affinity for the target RNA to allow post-hybridization RNaseH degradation. We report a phase 2 randomised, open-label, parallel group study of subcutaneously administered ATL1103 in patients with active acromegaly. Appr...

ea0031cmw2.2 | How Do I Do It? | SFEBES2013

How do I investigate and manage hypomagnesaemia?

Ayuk John

Serum magnesium concentration is regulated by the balance between intestinal absorption and renal excretion. Hypomagnesaemia is relatively common, with an estimated prevalence in the general population ranging from 2.5 to 15%. It may result from inadequate magnesium intake, increased gastrointestinal or renal loss, or redistribution from extracellular to intracellular space. Drug-induced hypomagnesaemia, particularly related to proton-pump inhibitor (PPI) therapy, is being inc...

ea0025cm3.4 | Pituitary radiotherapy: what are the options? | SFEBES2011

Radiotherapy, cognition and cerebrovascular disease: what is the evidence?

Ayuk John

Contemporary management of pituitary tumours is based on a multidisciplinary approach involving surgery, radiotherapy (RT) and medical therapy. External beam RT significantly reduces the likelihood of tumour re-growth following surgery for non-functioning pituitary adenomas and suppresses hypersecretion in hormonally-active tumours. However, over the years, a number of potentially significant complications of pituitary RT have been described.Radiation ma...

ea0087p15 | Poster Presentations | UKINETS2022

Management and outcome of pituitary metastasis from a bronchial carcinoid tumour presenting with ocular symptoms

Shah Husnain , Ayuk John

Metastasis to the pituitary gland is a rare occurrence. Here we discuss our experience managing a patient with pituitary neuroendocrine metastasis who first presented with ocular symptoms. A 65-year-old lady presented in July 2015 with progressive diplopia. An MRI scan revealed a pituitary mass lesion with aggressive features and two abnormal enhancing nodules within the brain white matter, raising suspicion of metastatic disease. Radiotherapy was commenced on the basis that t...

ea0050ep049 | Clinical Biochemistry | SFEBES2017

‘2’ much of a problem with hypoglycaemia

Sukumar Nithya , Venkataraman Hema , Ayuk John

Background: An 88 year old gentleman was referred to the endocrine team as an inpatient with recurrent episodes of spontaneous hypoglycaemia. These occurred in the early hours of the morning when he was found to be unrousable from sleep. There was no background history of diabetes. He was under the oncology team on this admission with pyrexia post-palliative chemotherapy with trabecitidine. Significant past medical history include metastatic solitar...

ea0050ep049 | Clinical Biochemistry | SFEBES2017

‘2’ much of a problem with hypoglycaemia

Sukumar Nithya , Venkataraman Hema , Ayuk John

Background: An 88 year old gentleman was referred to the endocrine team as an inpatient with recurrent episodes of spontaneous hypoglycaemia. These occurred in the early hours of the morning when he was found to be unrousable from sleep. There was no background history of diabetes. He was under the oncology team on this admission with pyrexia post-palliative chemotherapy with trabecitidine. Significant past medical history include metastatic solitar...

ea0044ep61 | (1) | SFEBES2016

A rare case of Follicular Stimulating Hormone (FSH) secreting pituitary adenoma in male

Kempegowda Punith , Ayuk John , Toogood Andrew

A 61-year-old man presented to his primary care service with complains of frequent hot flushes, dizziness and headache. Following initial screening, an incidental pituitary lesion was diagnosed on computed tomography (CT) scan and hence was referred to specialist review. Further detailed history revealed similar presentation with dizziness and hot flushes two and a half years ago. He was then diagnosed with essential hypertension after a negative work-up for Cushing disease. H...

ea0059ep46 | Clinical practice, governance & case reports | SFEBES2018

More than meets the eye - an unusual presentation of Cushing’s syndrome with bilateral central retinal vein occlusion

Kalaria Tejaskumar , Ayuk John , Buch Harit

A 53-year old male presented to his optician with blurring of vision on the right and was diagnosed to have branch retinal vein occlusion. Over the next 6 weeks he manifested further visual impairment, initially due to right central retinal venous occlusion (CRVO) and after another 3 months left CRVO. He received intravitreal Ranibizumab injections and timolol-dorzolamide eye drops in both eyes. Soon after this, he had a hospital admission for infected submandibular gland and ...